Fu Wai Hospital
Welcome,         Profile    Billing    Logout  
 16 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gao, Runlin
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

Recruiting
3
1600
RoW
rhNRG-1, Neucardin™, Placebo
Zensun Sci. & Tech. Co., Ltd.
Chronic Heart Failure
02/26
02/26
China XT, NCT03314857: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population

Completed
N/A
67
RoW
SAPIEN XT THV with the NovaFlex+ delivery system
Edwards Lifesciences
Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
07/18
06/23
IBS-FIM, NCT03509142: A First-in-Man Study of IBS

Completed
N/A
45
RoW
Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System, IBS
Lifetech Scientific (Shenzhen) Co., Ltd.
Single Coronary Vessel Disease
07/19
12/23
FUTURE-II, NCT02890160: A Trial of Firesorb in Patients With Coronary Artery Disease:

Active, not recruiting
N/A
430
RoW
Firesorb, XIENCE
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
10/20
10/24
NCT04893603: To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic Stenosis

Recruiting
N/A
120
RoW
Transcatheter Aortic Valve System
Chengdu Silara Meditech Inc.
Aortic Valve Stenosis
12/22
12/26
IRONMAN-III, NCT05205499: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Active, not recruiting
N/A
1059
RoW
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Biotyx Medical (Shenzhen) Co., Ltd.
Coronary Artery Disease
08/24
08/28
Xu, Bo
NCT06729892: Feasibility of Closed-loop TCI Based on New EEG Baseline in the Presence of Low Dose of Esketamine

Not yet recruiting
4
120
NA
Esketamine at low dose, new BIS baseline, an equivalent dose of saline, original BIS baseline
bo xu
General Anesthesia With Propofol, Closed-Loop
04/25
05/25
BIOHEART-II, NCT03284255: Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Active, not recruiting
N/A
431
RoW
study group, BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System, control group, Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
Shanghai Bio-heart Biological Technology Co., Ltd., CCRF Inc., Beijing, China
Coronary Artery Disease, Antineoplastic Agents
08/20
08/24
FUTURE-II, NCT02890160: A Trial of Firesorb in Patients With Coronary Artery Disease:

Active, not recruiting
N/A
430
RoW
Firesorb, XIENCE
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
10/20
10/24
FAVORIII, NCT03656848: The FAVOR III China Study

Active, not recruiting
N/A
3847
RoW
QFR, Quantitative Flow Ratio, Angiography, Coronary angiography
China National Center for Cardiovascular Diseases
Coronary Artery Disease, Myocardial Ischaemia, Coronary Circulation, Coronary Stenosis, Percutaneous Coronary Intervention
02/21
02/25
IRONMAN-III, NCT05205499: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Active, not recruiting
N/A
1059
RoW
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Biotyx Medical (Shenzhen) Co., Ltd.
Coronary Artery Disease
08/24
08/28
FWCTO, NCT03461367: CTO Registry From Insight of IVUS in Fuwai Hospital

Active, not recruiting
N/A
5000
RoW
China National Center for Cardiovascular Diseases
Coronary Heart Disease, Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention, Intravascular Ultrasound
12/24
12/25
NCT05669222: The FAVOR V AMI Trial

Not yet recruiting
N/A
5000
NA
FAST Technique, The next-generation quantitative flow ratio and radial wall strain, Angiography, Coronary angiography
China National Center for Cardiovascular Diseases
ST-Segment Elevation Myocardial Infarction, Multivessel Coronary Artery Disease, Percutaneous Coronary Intervention
06/25
06/28
CHART-OPTIMIZE, NCT05125107: PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis

Not yet recruiting
N/A
1607
NA
Quantitative Flow Ratio derived PPG and dQFR/ds
Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
12/21
03/22
CHART-ORIGIN, NCT05104580: PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention

Not yet recruiting
N/A
1395
NA
Quantitative Flow Ratio derived PPG
Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
01/22
03/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gao, Runlin
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

Recruiting
3
1600
RoW
rhNRG-1, Neucardin™, Placebo
Zensun Sci. & Tech. Co., Ltd.
Chronic Heart Failure
02/26
02/26
China XT, NCT03314857: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population

Completed
N/A
67
RoW
SAPIEN XT THV with the NovaFlex+ delivery system
Edwards Lifesciences
Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
07/18
06/23
IBS-FIM, NCT03509142: A First-in-Man Study of IBS

Completed
N/A
45
RoW
Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System, IBS
Lifetech Scientific (Shenzhen) Co., Ltd.
Single Coronary Vessel Disease
07/19
12/23
FUTURE-II, NCT02890160: A Trial of Firesorb in Patients With Coronary Artery Disease:

Active, not recruiting
N/A
430
RoW
Firesorb, XIENCE
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
10/20
10/24
NCT04893603: To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic Stenosis

Recruiting
N/A
120
RoW
Transcatheter Aortic Valve System
Chengdu Silara Meditech Inc.
Aortic Valve Stenosis
12/22
12/26
IRONMAN-III, NCT05205499: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Active, not recruiting
N/A
1059
RoW
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Biotyx Medical (Shenzhen) Co., Ltd.
Coronary Artery Disease
08/24
08/28
Xu, Bo
NCT06729892: Feasibility of Closed-loop TCI Based on New EEG Baseline in the Presence of Low Dose of Esketamine

Not yet recruiting
4
120
NA
Esketamine at low dose, new BIS baseline, an equivalent dose of saline, original BIS baseline
bo xu
General Anesthesia With Propofol, Closed-Loop
04/25
05/25
BIOHEART-II, NCT03284255: Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Active, not recruiting
N/A
431
RoW
study group, BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System, control group, Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
Shanghai Bio-heart Biological Technology Co., Ltd., CCRF Inc., Beijing, China
Coronary Artery Disease, Antineoplastic Agents
08/20
08/24
FUTURE-II, NCT02890160: A Trial of Firesorb in Patients With Coronary Artery Disease:

Active, not recruiting
N/A
430
RoW
Firesorb, XIENCE
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
10/20
10/24
FAVORIII, NCT03656848: The FAVOR III China Study

Active, not recruiting
N/A
3847
RoW
QFR, Quantitative Flow Ratio, Angiography, Coronary angiography
China National Center for Cardiovascular Diseases
Coronary Artery Disease, Myocardial Ischaemia, Coronary Circulation, Coronary Stenosis, Percutaneous Coronary Intervention
02/21
02/25
IRONMAN-III, NCT05205499: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Active, not recruiting
N/A
1059
RoW
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Biotyx Medical (Shenzhen) Co., Ltd.
Coronary Artery Disease
08/24
08/28
FWCTO, NCT03461367: CTO Registry From Insight of IVUS in Fuwai Hospital

Active, not recruiting
N/A
5000
RoW
China National Center for Cardiovascular Diseases
Coronary Heart Disease, Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention, Intravascular Ultrasound
12/24
12/25
NCT05669222: The FAVOR V AMI Trial

Not yet recruiting
N/A
5000
NA
FAST Technique, The next-generation quantitative flow ratio and radial wall strain, Angiography, Coronary angiography
China National Center for Cardiovascular Diseases
ST-Segment Elevation Myocardial Infarction, Multivessel Coronary Artery Disease, Percutaneous Coronary Intervention
06/25
06/28
CHART-OPTIMIZE, NCT05125107: PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis

Not yet recruiting
N/A
1607
NA
Quantitative Flow Ratio derived PPG and dQFR/ds
Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
12/21
03/22
CHART-ORIGIN, NCT05104580: PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention

Not yet recruiting
N/A
1395
NA
Quantitative Flow Ratio derived PPG
Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
01/22
03/22

Download Options